Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry

This article was originally published in The Pink Sheet Daily

Executive Summary

The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.

You may also be interested in...



India Launches Probe Following Damning Evidence Of Irregularities In Product Approvals

Government assembles committee to investigate validity of drug approvals without required clinical trials in India.

India Launches Probe Following Damning Evidence Of Irregularities In Product Approvals

Government assembles committee to investigate validity of drug approvals without required clinical trials in India.

Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility

MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants

Related Content

Topics

UsernamePublicRestriction

Register

PS072283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel